Research Studies



Currently enrolling studies:

(#308)  Essential Tremor (JZP385-201) 
Treatment of Adults With Moderate to Severe Essential Tremor: Essential tremor (ET) is a neurological disorder that causes your hands, head, trunk, voice or legs to shake rhythmically.
  1. Participant must be 18 to 80 years of age inclusive, at the time of signing the informed consent.\


(#237) Relapse Remitting Multiple Sclerosis (PTI-307-201 VISTA) 
  1. Subject is fluent in English.
  2. Male or female 18 to 50 years of age, inclusive, at the first Screening visit.
  3. A diagnosis of relapsing-remitting multiple sclerosis (RRMS) according to the 2017 Revised McDonald Criteria.


(#196) Relapse Remitting Multiple Sclerosis (COMB157GUS09 SOSTOS) 
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab (KESIMPTA) versus staying on their continued current therapy.
  1. Age 18-45 years
  2. Diagnosis of RRMS per McDonald Criteria (2017)
  3. EDSS 0-5.5 (Inclusive)
  4. Able to obtain MRI and attend study visits at sites
  5. Willing to use wearable device as specified in the protocol
  6. Able to provide blood sample
  7. On a current DMT with approved label use for treatment of RRMS at least 6 months prior to Screening
  8. No relapse reported within 6 months prior to Screening
  9. Patients may enroll in the trial if they have subclinical disease activity as measured by MRI prior to enrollment. An absence of MRI activity is not exclusionary.


(#384) Relapse Remitting Multiple Sclerosis (BLS-11-404 SIMPLE) 
Adult participants with a diagnosis of RRMS who have been receiving continuous treatment with Bafiertam monotherapy per the approved product label for no more than 3 months (90 days) are eligible to enroll in the study. Their satisfaction with Bafiertam treatment will be assessed using a 9-Item Treatment Satisfaction Questionnaire for Medication (TSQM-9). To be included in the study, patients.
  1. Male or non-pregnant female aged 18 years and older.
  2. Participants diagnosed with Relapsing forms of multiple sclerosis R(RMS) and satisfy the approved therapeutic indication for Bafiertam per the approved product labeling.
  3. Participants may enroll if they are within 90 days of initiating therapy with Bafiertam.